Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the American Heart Association Scientific Session...
November 11 2019 - 09:00AM
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that
additional results from COSMIC-HF (
Chronic
Oral
Study of
Myosin Activation to
Increase
Contractility in
Heart
Failure), a Phase 2 trial evaluating omecamtiv
mecarbil in patients with chronic heart failure, will be
presented in an Abstract Rapid Fire Oral presentation at the
American Heart Association Scientific Sessions 2019 in Philadelphia
on November 18, 2019.
Title: The Effect of the
Cardiac Myosin Activator, Omecamtiv Mecarbil, on Diastolic Filling
and Function in Chronic Systolic Heart Failure (COSMIC-HF)
Poster Presenter: Tor Biering-Sørensen, M.D.,
Herlev & Gentofte Hospital and Associate Professor, University
of CopenhagenDate: November 18,
2019Session: Pharmacological Therapy in
HF/Cardiomyopathy: The Next Important Indication or
Agent?Session Number:
HF.RFO37Time: 2:45 – 2:50 PM Poster
Number: RF299Location: Zone 4, Science
and Technology Hall
About Omecamtiv Mecarbil and the Phase 3
Clinical Trials Program
Omecamtiv mecarbil is a novel, selective cardiac
myosin activator, also known as a cardiac myotropei, that binds to
the catalytic domain of myosin. Preclinical research has
shown that cardiac myotropes increase cardiac contractility without
affecting intracellular myocyte calcium concentrations or
myocardial oxygen consumption.ii,iii,iv Cardiac myosin is the
cytoskeletal motor protein in the cardiac muscle cell that is
directly responsible for converting chemical energy into the
mechanical force resulting in cardiac contraction.
Omecamtiv mecarbil is being developed for the
potential treatment of heart failure with reduced ejection fraction
(HFrEF) under a collaboration between Amgen and Cytokinetics, with
funding and strategic support from Servier. Omecamtiv mecarbil is
the subject of a comprehensive Phase 3 clinical trials program
comprised of GALACTIC-HF (Global
Approach to Lowering
Adverse Cardiac Outcomes
Through Improving
Contractility in Heart
Failure), a large, Phase 3 global cardiovascular
outcomes study and METEORIC-HF (Multicenter
Exercise Tolerance
Evaluation of Omecamtiv Mecarbil
Related to Increased
Contractility in Heart
Failure), a Phase 3 clinical trial designed to
evaluate the effect of treatment with omecamtiv mecarbil compared
to placebo on exercise capacity.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and best-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating with Amgen Inc.
(Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of an international
clinical trials program in patients with heart failure including
GALACTIC-HF and METEORIC-HF. Amgen holds an exclusive worldwide
license to develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization in Europe and
certain other countries. Cytokinetics is collaborating with
Astellas Pharma Inc. (Astellas) to develop reldesemtiv, a fast
skeletal muscle troponin activator (FSTA) for diseases of
neuromuscular dysfunction, including SMA and ALS. Astellas holds an
exclusive worldwide license to develop and commercialize
reldesemtiv. Licenses held by Amgen and Astellas are subject to
specified co-development and co-commercialization rights of
Cytokinetics. Cytokinetics is also developing CK-274, a novel
cardiac myosin inhibitor that company scientists discovered
independent of its collaborations, for the potential treatment of
hypertrophic cardiomyopathies. Cytokinetics continues its over
20-year history of pioneering innovation in muscle biology and
related pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics' and its partners'
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management's current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics' business outlined in Cytokinetics'
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics' actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:CytokineticsDiane
WeiserVice President, Corporate Communications, Investor
Relations(415) 290-3060
i Psotka MA, Gottlieb SS, Francis GS et al. Cardiac Calcitropes,
Myotropes, and Mitotropes. JACC. 2019; 73:2345-53.
ii Planelles-Herrero VJ, Hartman JJ, Robert-Paganin J. et
al. Mechanistic and structural basis for activation of cardiac
myosin force production by omecamtiv mecarbil. Nat
Commun. 2017;8:190.
iii Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac
function by a cardiac myosin activator in conscious dogs with
systolic heart failure. Circ Heart Fail. 2010; 3: 522-27.
iv Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc
K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R. Cardiac
myosin activation: a potential therapeutic approach for systolic
heart failure. Science. 2011 Mar 18;331(6023):1439-43.
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2023 to Mar 2024